VTE

Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE) Medications Chart

List of medications indicated for the prophylaxis and/or treatment of deep vein thrombosis (DVT) / pulmonary embolism (PE) with usual adult dosage.

VTE Risk May be Higher in Patients Who Receive Chemotherapy

VTE Risk May be Higher in Patients Who Receive Chemotherapy

By

Risk of venous thromboembolism (VTE) may be higher in patients with cancer who receive chemotherapy.

Dalteparin Thromboprophylaxis Associated With Reduced Risk of VTE in Cancer

Dalteparin Thromboprophylaxis Associated With Reduced Risk of VTE in Cancer

By

Thromboprophylaxis with dalteparin is associated with a non-significant decreased risk of venous thromboembolism (VTE).

Tinzaparin May Not Lower Risk of Recurrent VTE in Active Cancer

Tinzaparin May Not Lower Risk of Recurrent VTE in Active Cancer

By

Among patients with active cancer, full-dose tinzaparin daily compared with warfarin did not significantly reduce the composite measure of recurrent VTE.

Occult Cancers Rare in Unprovoked Venous Thromboembolism

Occult Cancers Rare in Unprovoked Venous Thromboembolism

By

Prevalence of occult cancer is low among patients with first unprovoked venous thromboebolism (VTE).

Inferior Vena Cava Filters in Patients with Cancer

Inferior Vena Cava Filters in Patients with Cancer

By

The placement of an inferior vena cava filter is understudied in patients with cancer and clear guidelines do not exist.

Anticoagulation May Be Safe for Patients with Brain Metastases

Anticoagulation May Be Safe for Patients with Brain Metastases

Therapeutic anticoagulation is safe for treating venous thromboembolism in patients with cancer that has metastasized to the brain.

Enoxaparin Efficacious, Feasible for Prevention of VTE in Advanced Pancreatic Cancer

Enoxaparin Efficacious, Feasible for Prevention of VTE in Advanced Pancreatic Cancer

By

Recent research shows that enoxaparin effectively prevents VTE complications in advanced pancreatic cancer without decreasing efficacy of chemotherapy.

Large Retroperitoneal Lymph Node Associated with VTE in Disseminated Germ Cell Tumors

Large Retroperitoneal Lymph Node Associated with VTE in Disseminated Germ Cell Tumors

Large retroperitoneal lymph node (RPLN) is associated with venous thromboembolism (VTE) in disseminated germ cell tumors (GCTs).

VTE Prophylaxis Guidelines Unchanged in Cancer Treatment

VTE Prophylaxis Guidelines Unchanged in Cancer Treatment

Thromboprophylaxis required throughout hospitalization for most patients with active cancer.

Managing Anticoagulation in Patients with Brain Tumors

Managing Anticoagulation in Patients with Brain Tumors

By

Patients with brain cancer are at increased risk of deep vein thrombosis and consequently pulmonary embolism.

Optimal Heparin Treatment in Residual Vein Thrombosis (RVT) Patients Found

Optimal Heparin Treatment in Residual Vein Thrombosis (RVT) Patients Found

Presence of residual vein thrombosis in cancer patients may help determine the optimal duration of LMWH treatment.

NSAIDs Tied to Venous Thromboembolism (VTE) Risk

NSAIDs Tied to Venous Thromboembolism (VTE) Risk

NSAIDs should be prescribed with caution, especially in patients already at a higher risk of VTE.

Venous Thromboembolism (VTE) Rate Low Post-Surgery

Venous Thromboembolism (VTE) Rate Low Post-Surgery

Independent predictors include older age, chronic steroid use, greater anesthesia time.

Eliquis Approved in Three New Indications

Eliquis Approved in Three New Indications

Eliquis has been approved for deep vein thrombosis, pulmonary embolism, and reduction of risk for both.

Human Papillomavirus (HPV) Test May Be More Accurate Than Pap Test for Cervical Cancer Screening

Human Papillomavirus (HPV) Test May Be More Accurate Than Pap Test for Cervical Cancer Screening

By

A review of data suggests that HPV testing alone every 3 years provides a high level of reassurance against cervical cancer.

Venous Thrombo-embolism Prophylaxis in the Outpatient Oncology Setting

Venous Thrombo-embolism Prophylaxis in the Outpatient Oncology Setting

By

While guidelines recommend against routine use, further investigation and data collection on this topic is warranted.

In Canada, HPV-Related Noncervical Cancers on the Rise

In Canada, HPV-Related Noncervical Cancers on the Rise

Registry data show increase in incidence rates of HPV-related oropharyngeal and anal cancers.

HPV Vaccine Doesn't Increase VTE Risk

HPV Vaccine Doesn't Increase VTE Risk

Risk for venous thromboembolism appears to be no higher after quadrivalent HPV vaccination.

VTE Rate is 13% in Head, Neck Cancer Surgeries

VTE Rate is 13% in Head, Neck Cancer Surgeries

The rate of venous thromboembolism is higher than previously reported in retrospective studies.

Targeted Therapies May Improve Survival in Patients with Ovarian Cancer

Targeted Therapies May Improve Survival in Patients with Ovarian Cancer

By

New cancer therapies and statins demonstrate efficacy in treating and perhaps even preventing ovarian cancer recurrence.

Tumor Emboli in Patients with Cancer: A Challenging Diagnosis

Tumor Emboli in Patients with Cancer: A Challenging Diagnosis

By

Tumor emboli can occur in patients with cancer and carry with them a risk for serious complications.

Public Reporting of Individual Hospital Cancer-Specific Quality Metrics Recommended

By

Major challenges exist for hospitals with respect to publicly reported cancer metrics, according to research presented at SSO 2013.

New Oral Anticoagulants: An Update Relevant to Treating Patients with Cancer

New Oral Anticoagulants: An Update Relevant to Treating Patients with Cancer

By

Oncologists should be aware of possible complications associated with administering anticoagulants to patients with cancer.

VEGF Receptor TKIs Not Associated with Increased Risk of Venous Thrombotic Events, Meta-Analysis Finds

By

Vascular endothelial growth factor receptor tyrosine-kinase inhibitors do not appear to be associated with an increased risk of venous thrombotic events in patients with advanced cancers.

ASH: First Int'l Good Clinical Practice Guidelines for Use of Antithrombotics

By

Global experts called on colleagues attending the 54th American Society of Hematology Annual Meeting and Exposition to help disseminate and implement the first International Good Clinical Practice Guidelines for the use of antithrombotics.

Cisplatin Significantly Increases Risk of VTEs in Patients with Advanced Solid Tumors

By

Patients with advanced solid tumors treated with cisplatin have a significant increased risk of venous thromboembolism compared with non-cisplatin-based chemotherapy.

ESA Increases VTE Risk but Does Not Affect OS in Women Administered Bevacizumab for Ovarian Cancer

By

Erythropoietin stimulating agents and granulocyte colony stimulating factor do not affect OS among patients with ovarian cancer who receive bevacizumab plus chemotherapy, but ESA is associated with a significantly-elevated risk of venous thrombotic events.

Unsuspected PE Does Not Up Mortality Risk in Cancer Patients

Unsuspected PE Does Not Up Mortality Risk in Cancer Patients

Unsuspected PE patients also have similar risk of recurrent VTE as those with clinically suspected PE.

Dr. E. David Crawford: Renal Cell Carcinoma Case Study

Dr. E. David Crawford: Renal Cell Carcinoma Case Study

Dr. E. David Crawford, Head Urologic Oncology at the University of Colorado, presents his case study on renal cell carcinoma (RCC).

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs